Pigmentation Disorders

Join us as leading experts discuss key data and perspectives from the late-breaking sessions at this year’s AAD meeting This March, experts from around the world gathered in Denver, Colorado, for the 2026 American Academy of Dermatology (AAD) Annual Meeting. ...

Prof. Thierry Passeron discusses key data from the upadacitinib Viti-Up studies, which provide the first strong Phase 3 evidence supporting a systemic treatment for non-segmental vitiligo. Results from the two parallel placebo-controlled studies showed that, by week 48, approximately 20% of patients treated with upadacitinib achieved T-VASI 50, compared with fewer than 6% in the placebo group, while around 25% achieved F-VASI 75 versus 6–7% with placebo. Prof. Passeron highlighted these findings as particularly important given the lack of approved systemic options for patients with extensive or active disease. He also noted that the studies demonstrated a favourable safety profile, with no new safety signals identified over 48 weeks, supporting upadacitinib’s potential role in the evolving treatment landscape for non-segmental vitiligo.

Could the first systemic therapy for non-segmental vitiligo soon be within reach? On 4 February 2026, AbbVie submitted regulatory applications to the FDA and EMA for upadacitinib, supported by positive phase III data in patients with non-segmental vitiligo

Phase 3 results show that upadacitinib, a JAK inhibitor, significantly improves repigmentation in adults and adolescents with non-segmental vitiligo. Across two global trials, upadacitinib achieved meaningful total body and facial repigmentation, with a safety profile consistent with previous findings.

The 2025 European Academy of Dermatology and Venereology (EADV) Congress brought over 20,000 delegates to Paris this September, showcasing the latest advances in the field. With more than 180 sessions and 600 expert speakers, the meeting highlighted innovations ranging from new biologics and novel agents to real-world evidence and patient-centred care. In this article, we share key highlights from the congress, spotlighting the breakthroughs and clinical insights set to shape the future of dermatology practice.

Expert insights on referral, risk stratification and treatment for patients with infantile haemangiomas.

This year, we are celebrating our inaugural touchDERMATOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform dermatology in the years to come. Representing a diverse range of expertise from across the globe, these highly accomplished clinicians are among the brightest minds shaping the future of dermatology. We had the pleasure of learning about their unique career journeys, motivations, and the inspirations that have guided their paths. They also shared their perspectives on the most exciting developments in dermatology today, along with their hopes for the future of the field. Congratulations to all our touchDERMATOLOGY Future Leaders, and thank you for sharing your stories, insights and ambitions with us.

We are delighted to introduce touchDERMATOLOGY Future Leader Dr Neelam Vashi, a highly accomplished dermatologist widely recognized for her expertise in cosmetic dermatology, skin of colour and laser medicine. In this Q&A, Dr Vashi shares the values and experiences that shaped her journey in dermatology, her perspective on patient-centred innovation and her vision for a more authentic understanding of beauty.

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.